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A B S T R A C T   
Background: Scientists suggest that soy isoflavones or the combination of soy isoflavones and soy protein may 
have beneficial effects on inflammation. Thus, the present study aims at conducting a systematic review and 
meta-analysis on randomized controlled trials (RCTs) in which the effect of soy isoflavones and the combination 
of soy isoflavones and soy protein on serum concentration of C-reactive protein (CRP) among postmenopausal 
women is assessed. 
Methods and materials: A literature searching was done to identify a breadth of related references in PubMed, 
Scopus, ISI Web of Science, Cochrane Library, and Clinicaltrials.gov up to December 2020. The mean change 
from baseline in the CRP concentrations and its standard deviation (SD) for both intervention and comparison 
groups were used to calculate the effect size. The summary of the overall effects and heterogeneity was estimated 
by using the DerSimonian and Laird random effects model. The protocol was registered in PROSPERO (No. 
CRD42020166053). 
Results: This study considered 23 articles for systematic review and 19 articles for meta-analysis. The overall 
effect presented a non-significant effect of soy isoflavones on serum CRP concentrations (WMD = 0.08 mg/L, 95 
% CI: -0.08, 0.24; p = 0.302) and the overall effect of the combination of soy isoflavones and soy protein 
indicated non-significant effect in serum levels of CRP (WMD= -0.02 mg/L 95 % CI: -0.12, 0.08; p = 0.715). 
Conclusion: Published RCTs did not provide strong evidence regarding beneficial effect of soy isoflavones or the 
combination of soy isoflavones and soy protein on serum CRP concentration among postmenopausal women.   
1. Introduction 
Local inflammation starts in fourth decade of life and increases 
during aging.1 The enhancement of proinflammatory cytokines causes 
oxidative stress and results in damage to various intracellular compo-
nents such as regulatory and structural proteins, DNA, and lipids.2 
C-reactive protein (CRP) considers as a hepatically-produced acute 
phase reactant protein. Its serum concentration is associated with 
inflammation3 and the high serum level of CRP is a predictor of ischemic 
stroke and first myocardial infarction in humans.4,5 According to 
Women’s Health Study, postmenopausal women with the highest CRP 
concentration at baseline had a 7-fold enhancement in myocardial 
infarction risk and 5-fold enhancement in any vascular event.6 Thus, it 
seems that high serum level of CRP can predict cardiovascular events 
especially among postmenopausal women. 
Beside the enhancement of inflammation, a reduction in endogenous 
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estrogen is also a reason for cardiovascular disease (CVD) among post-
menopausal women.7 Hormone replacement therapy (HRT) has favor-
able effects on endothelial function, antioxidant protection, blood lipids 
and lipoprotein concentrations, and vascular reactivity.8,9 Despite the 
positive effects of estrogen therapy on clinical markers, the benefits of 
HRT for postmenopausal women remain controversial.10 Polyphenolic 
isoflavones such as genistein and daidzein are presented in soy and 
structurally are similar to estradiol11 and therefore they can bind to 
estrogen receptor β in vascular wall12–16. 
Animal experiments and cell studies propose that in addition to soy 
isoflavones the genistein and daidzein have anti-inflammatory and lipid 
lowering effects.17,18 Scientists suggest that soy isoflavones may reduce 
inflammatory mediators through the inhibition of tyrosine kinase.19,20 
Besides soy isoflavones, soy protein is recommended as a food for car-
diovascular protection due to its favorable impact on blood pressure and 
cholesterol.21,22 Some studies have indicated that substitution of animal 
protein with soy protein might reduce circulating levels of inflammatory 
mediators23,24. 
Previous information regarding soy consumption and inflammatory 
mediators among postmenopausal women is far from conclusive. Some 
randomized clinical trials (RCTs) support the effectiveness of soy food 
consumption on proinflammatory cytokine reduction,25–29 while others 
do not.30–36 A meta-analysis of 14 trials conducted in 2011 examined soy 
isoflavones effect on serum concentration of CRP among post-
menopausal women and their results proposed non-significant effect of 
soy isoflavones on CRP.37 
It should be noted that we performed an updated systematic review 
and meta-analysis to report a summary of RCTs exploring the effect of 
soy isoflavones and soy isoflavones plus soy protein on CRP. 
2. Materials and methods 
PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) checklists were used for all steps of conducting the 
present systematic review and meta- analysis.38 The protocol was 
registered in PROSPERO (No. CRD42020166053). 
2.1. Literature search 
In order to identify RCTs, a literature search was conducted using 
PubMed, Scopus, and ISI Web of Science, Cochrane Library, and Clin-
icaltrials.gov up to December 2020 exploring the effect of soy iso-
flavones, and soy isoflavones plus soy protein on serum concentration of 
CRP among postmenopausal women. These databases were searched by 
following related medical subject heading (MeSH) and non-MeSH terms 
for the most important inflammatory mediators, soy and clinical trial: 
"C-Reactive Protein", "Protein-C Reactive", "CRP", "Tumor Necrosis 
Factor-alpha", "Tumor Necrosis Factor", "Tumor Necrosis Factorα", 
"TNFα", "TNF-α", "Cachectin", "Cachexin", "Interleukin-6", "Interleukin6", 
"IL6", "IL-6", "E-Selectin", "E-Selectin", "Selectin E", "SelectinE", "ESe-
lectin", "Intercellular Adhesion Molecule-1", "Intercellular Adhesion 
Molecule1", "Intercellular Adhesion Molecule", "ICAM-1", "ICAM1", 
"Vascular Cell Adhesion Molecule-1", "Vascular Cell Adhesion Mole-
cule1", "Vascular Cell Adhesion Molecule", "VCAM-1", "VCAM1", 
Inflammat, "Soy", "Soy Foods", "Soy Food", "Soy, Food", "Soy, Foods", 
"Soyfood", "Soyfoods", "Foods Soy", "Soy Cheese", "Soy Cheeses", "Soy 
Sauce", "Soysauce", "Soy Bean Curd", "Texturized Soy Protein", "Textur-
ized Soy Proteins", "Texturized Vegetable Protein", "Soya", "Natto", 
"Tempeh", "Tofu", "Miso", "Soy Milk", "Milk Soy", "Milk, Soy", "Soy 
Beverage", "Soy Beverages", "Soy, Beverage", "Soybeans", "Soybean", 
"Soy Bean", "Soy Beans", "Glycine max", "Soybean Proteins", "Soy Bean 
Proteins", "Soy Protein", "Soy Proteins", "Proteins Soy", "Protein Soy", 
"Genistein", "Soy Products", "Isoflavones", "Isoflavone", "Homoiso-
flavones", "3-Benzylchroman-4-Ones", "3-Benzylidene-4-Chromanones", 
"Phytoestrogens", "Phytoestrogen", "Phyto-Estrogen", "Plant Estrogen", 
"Plant Estrogens", "Equol", “Clinical Trials”, “Clinical Trial”, “RCT”. 
Boolean operators, quotation marks, parentheses, and asterisks were 
used to create our search strategy. Through searching databases based 
on just CRP a few articles might be missed, therefore; we also applied 
key words related to the most important inflammatory mediators. All 
found papers by systematic search were imported to reference manager 
software (EndNote X7) and two reviewers (M.H and A.Gha) separately 
checked titles and abstracts of exported papers in order to identify the 
relevant RCTs. Reference list of relevant reviews and included RCTs 
were hand searched to find any other relevant RCTs. There wasn’t any 
restriction on publication time and any discrepancies were solved 
through consulting with a third investigator (A.Gho). 
2.2. Eligibility criteria for study 
PICOS (Patient/Population, Intervention, Comparison, Outcome, 
Study types) framework was used as inclusion criteria for this systematic 
review and meta-analysis. Original investigations with RCT design 
conducted among postmenopausal women were considered for inclu-
sion in this study. To be inclusion, trials should report the effects of soy 
isoflavones or soy isoflavones plus soy protein on serum concentration of 
CRP. After reading the full texts of retrieved studies, RCTs with 
following criteria were not taken into account in this systematic review 
and meta-analysis: 1) taking other nutrient supplements beside soy in 
intervention group; 2) being done trials without comparison group; 3) 
not reporting information related to serum concentration of CRP at 
baseline or after intervention and any data for computing it; 4) reporting 
serum concentration of CRP in figures; 5) not reporting the dose of soy 
isoflavones and soy protein in natural soy product. In addition, our study 
was restricted to the articles published in English. 
2.3. Data extraction 
Two independent authors (M.H and A.Gha) done data extraction to 
elicit the following information: the author’s first name, the year of 
publication, the country where RCTs were conducted, body mass index 
(BMI), sample size, trial design, age range and/or mean, soy isoflavones 
and soy protein dose and source, intervention duration, placebo kind, 
subjects’ health status, mean of serum concentration of CRP and its 
corresponding standard deviation (SD) before and after intervention. 
Any discrepancies in this stage also were resolved through consulting 
with a third reviewer (A.Gho). We converted all CRP measurements into 
the same unit (mg/L). Studies which had more than one intervention or 
comparison group were included separately. 
2.4. Quality assessment 
Two reviewers (M.H and A.Gho) separately assessed the quality of 
included trials by Cochrane Collaboration’s tool.39 Following items are 
included in this tool for risk of bias assessment: I) selection bias: A) 
random sequence generation, B) allocation concealment; II) reporting 
bias; III) performance bias; IV) detection bias; IV) attrition bias. Each 
item was judged as “unclear risk of bias”, “high risk of bias,” or “low risk 
of bias”. We considered included RCTs as “good” quality if they had the 
least low risk of bias for three criteria, as “fair” if they had low risk for 
two criteria, and “weak” if they had low risk for less than two criteria.39 
2.5. Data synthesis and statistical analysis 
The current meta-analysis was performed by extracting mean dif-
ferences (MDs) and their SDs for CRP (mg/l). Additionally, the values 
were calculated using the data extracted from the included articles in 
which MDs and SDs weren’t reported. Based on Cochrane Handbook,40 
the mean change from baseline in the CRP concentrations and its SD for 
both intervention and comparison groups were used to calculate the 
effect size. In order to estimate the mean of CRP concentration, Hozo’s 
method41 was used. Moreover, SDs were obtained from multiplying 
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standard errors (SEs) divided by square root of the sample size in studies 
which reported SEs. The summary of the overall effects and heteroge-
neity was estimated by using the DerSimonian and Laird random effects 
model,42 if a heterogeneity test was statistically significant. Statistical 
heterogeneity of intervention effects was measured using Cochran’s Q 
test and I-squared statistic. Heterogeneity was considered substantial if 
p-value was ≤0.10 in Cochran’s Q test or value of the I-squared statistic 
was ≥50 %.43 
Subgroup analyses were performed to explore sources of heteroge-
neity which included soy isoflavones dose, soy protein dose, trial design, 
intervention duration, mean of baseline CRP concentration, health sta-
tus of participants, sample size, geographical region, age of participants, 
BMI, quality assessment of articles and year of study publication. Meta- 
regression was used to examine the impact of moderator variables on 
effect sizes and to compute adjusted effect of soy isoflavones dose and 
soy protein dose on effect sizes after controlling for other variables. 
Visual inspection of Begg’s funnel plot, Begg’s rank correlation, and 
Eggar’s weighted regression tests were used to assess the presence of 
publication bias in the meta-analysis.44,45 Sensitivity analysis was con-
ducted using the leave-one out method to specify the effect of each study 
on the overall effect size. Ninety-five percent confidence intervals were 
provided for all calculated effect sizes. All analyses were performed 
using STATA version15 (Stata Corp, Collage Station, TX). 
3. Results 
3.1. Study selection 
Systematic search of databases retrieved 4387 articles. By removing 
duplicate papers, 2955 articles remained for reading title and abstract. 
Among these articles, 2833 were excluded from investigations, thus 122 
RCTs remained for reading full text. Likewise, 99 articles were excluded 
due to the following reasons: ninety-two articles did not measure CRP or 
not conducted among postmenopausal women, there was a non-English 
article, five articles reported using other nutrients beside soy interven-
tion, and CRP unit was not reported in one article (Fig. 1). Therefore, 23 
papers remained eligible for being investigated in this systematic review 
(Table 1).24–36,46–55 Concerning the data inadequacy in four 
articles,28,32,50,55 nineteen articles were finally included in this 
meta-analysis.24–27,29–31,33–36,46–49,51–54 
3.2. Study characteristics 
By conducting this study, we found that ten articles assessed the 
effect of soy isoflavones,27,28,30,33,34,46–48,51,55 nine articles assessed the 
effect of soy isoflavones plus soy protein,24–26,31,32,35,50,53,54 and four 
articles assessed the effect of both soy isoflavones and soy isoflavones 
plus soy protein.29,36,49,52 Participants involved in seven articles 
received soy isoflavones plus soy protein by taking natural soy 
products.24–26,29,31,50,54 That is to say, seven articles had two 
Fig. 1. Flowchart of study selection process.  
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Table 1 




Subjects Age and BMI* 
(mean ± SD) 









women without metabolic 
syndrome 
N = 49 
Age: 54.6 ± 5.8 




0.5 cups/day soy nuts 
(containing 25 g of soy 
protein and 101 mg of 
aglycone isoflavones) 








women with metabolic 
syndrome 
N = 11 
Age: 54.1 ± 6.5 




0.5 cups/day soy nuts 
(containing 25 g of soy 
protein and 101 mg of 
aglycone isoflavones) 










N = 20 
Age: 58 ± 5 




70 mg/day isoflavones 
(44 mg of diadzein, 16 
mg of glycitein, and 10 
mg of genistein) 











N = 20 
Age: 58 ± 5 




70 mg/day isoflavones 
(44 mg of diadzein, 16 
mg of glycitein, and 10 
mg of genistein) 










with the metabolic 
Syndrome 
N = 42 
Age: 57 ± 1.94 




30 g/day soy nut 
(containing 11.25 g/ 
day protein with 84 
mg/day isoflavones) 









with the metabolic 
Syndrome 
N = 42 
Age: 57 ± 1.94 




30 g/day soy protein 
(containing 15 g/day 
protein with 102 mg/ 
day isoflavones) 







Older women with 
metabolic syndrome 
N = 50 






35 g/day roasted soy- 
nut (containing 92.5 mg 
isoflavines and 13.8 g 
protein) 








Older women with 
metabolic syndrome 
N = 50 






35 g/day textured soy 
protein (containing 
117.2 mg isoflavines 
and 18.2 g protein) 










white and African 
American women 
N = 33 
Age: 54.4 ± 3.3 




soy shakes (containing 
20 g soy protein plus 
160 mg isoflavones) 
Casein without 
isoflavones 










N = 57 
Age: 55.4 ± 3.7 





60 mg/day isoflavones 
(30 mg genistein and 30 
mg daidzein) 










N = 55 














with diet-controlled type 2 
diabetes 
N = 26 
Age: N/M 






132 mg/day isoflavones 
(53 % genistein, 37 % 














N = 34 
Age: 57.7 ± 6.0 





soy protein isolated (26 
± 5 g protein containing 
44 ± 8 mg isoflavones 
per day) 




Hall, W. L 
Age: 57.7 ± 5.4 
BMI: 25 ± 2.9 
Randomized, 
double-blind, 
50 mg/day isoflavones cereal bars 8 CRP decreased 
significantly in 
(continued on next page) 
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Subjects Age and BMI* 
(mean ± SD) 



















Overweight and obese 
postmenopausal women 
N:29 
Age: 59.5 ± 4.5 





daily dose of isoflavones 
(containing 44 mg of 
daidzein, 16 mg 
of glycitein, and 10 mg 
of genistein) 
cellulose 24 CRP decrease 
significantly 
12.1 










Low isoflavone soy 
protein foods (supplied 
10 mg/day isoflavones 
and 52 g/day soy 
protein) 














High isoflavone soy 
protein foods (supplied 
73 mg/day isoflavones 
and 50 g/day soy 
protein) 










N = 180 
Age: 57.6 ± 5.3 




40 g low-fat milk 
powder + 63 mg 
daidzein 
40 g low-fat milk 
powder 










N = 180 
Age: 57.6 ± 5.3 




40 g/day soy flour 
(containing 12.8 g 
protein and 49.8 mg 
total isoflavones (23.2 
mg daidzein and 19.4 
mg genistein)) 
40 g low-fat milk 
powder 











N = 120 
Age: 56.4 ± 4.7 




15-g/day soy protein 
and 100-mg isoflavone 
(35 mg daidzin, 59 mg 
genistin and 4 mg 
15 g/day milk 
protein 










N = 120 
Age: 56.4 ± 4.7 




15-g/day soy protein 
and 100-mg isoflavone 
(35 mg daidzin, 59 mg 
genistin and 4 mg 
15 g/day milk 
protein 










N = 120 
Age: 56.4 ± 4.7 




100-mg isoflavone (35 
mg daidzin, 59 mg 
genistin and 4 mg 
glycitin) 
15 g/day milk 
protein 










N = 120 
Age: 56.4 ± 4.7 




100-mg isoflavone (35 
mg daidzin, 59 mg 
genistin and 4 mg 
glycitin) 
15 g/day milk 
protein 










N = 87 
Age: 56.1 ± 3.51 




80 mg/day isoflavone 
(60.8 mg of genistein, 
16 mg of daidzein and 
3.2 mg of glicitein) 










N = 65 
Age: 56.7 ± 3.5 




80 mg of isofl avones 
(60.8 mg genistein, 16 
mg daidzein and 3.2 mg 
glicitein) 










N = 65 
Age: 56.7 ± 3.5 




80 mg of isofl avones 
(60.8 mg genistein, 16 
mg daidzein and 3.2 mg 
glicitein) 










N = 65 
Age: 56.7 ± 3.5 




80 mg of isofl avones 
(60.8 mg genistein, 16 
mg daidzein and 3.2 mg 
glicitein) 








N = 65 
Age: 56.7 ± 3.5 




80 mg of isoflavones 
(60.8 mg genistein, 16 
mg daidzein and 3.2 mg 
glicitein) 
Nothing 96 CRP did not 
change 
significantly 
(continued on next page) 
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intervention groups and one comparison group24,26,29,31,36,49,52 and one 
article had two intervention groups and two comparison groups,25 
therefore; we considered every article as two separate articles and 
separate effect sizes were calculated. In three studies by Llaneza, P 
et al.,48 Liu Z, M et al.,36 and Aubertin-Leheudre, M et al.,30 CRP con-
centration was reported in regular periods over intervention duration, so 
we calculated separate effect sizes for each treatment duration which 
CRP concentration was reported. Altogether, a total of 33 datasets (17 
datasets for soy isoflavones and 16 datasets for soy isoflavones plus soy 
protein) from 19 studies with 1407 subjects were analyzed in our 
meta-analysis. 
Among twenty-three articles, nine articles were done by cross-over 




Subjects Age and BMI* 
(mean ± SD) 











Healthy older women 
N = 47 
Age: 73 ± 5.7 





18 g/day soy protein 
and isoflavone tablets 
(105 mg/d isoflavone) 
Maltodextrin and 
animal protein 









Healthy Older women 
N = 48 
Age: 73 ± 5.7 





105 mg/d isoflavone Maltodextrin and 
animal protein 

















0.5 cups of soy nuts 
(containing 25 g soy 
protein and 101 mg 
aglycone 
Isoflavones) 

















0.5 cups of soy nuts 
(containing 25 g soy 
protein and 101 mg 
aglycone Isoflavones) 








Overweight or obese 
postmenopausal women 










70 mg/day soy 
isoflavones 












N = 37 
Age: 55.4 ± 3.9 




706 mL soymilk/ 
d (containing 71.6 mg 
isoflavones and 18 g/ 
day soy protein) 












N = 34 
Age: 55.4 ± 3.9 















women using tibolone 
N = 36 
Age: 57.7 ± 0.8 





52 g/day of soy protein 
containing 63 mg of 
genistein, 43 mg of 
daidzein and 6 mg of 
glycitein, altogether 
112 mg of isoflavones 










with abdominal obesity 
N:15 





soy nuts (containing 30 
g/d soy protein and 48 
mg/d isoflavones) 










N = 40 
Age: 49.5 ± 3.0 




40 mg/day of genistein, Nothing 24 CRP did not 
change 
significantly  
† : CRP: C-reactive protein. 
* : BMI: Body Mass Index. 
‡ : N/M: Not mention. 
Δ : RCT: Randomized clinical trial. 
Φ : means (95 % confidence interval). 
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design,24–2735,46,50,53,54 and fourteen articles were done by parallel 
design.28–34,36,47–49,51,52,55 Soy isoflavones dose ranged from 10 mg/day 
to 160 mg/day and treatment duration varied from four to 96 weeks. 
Also, with regards to the subjects’ health status, thirteen RCTs indicated 
soy supplements effects on healthy postmenopausal 
women,24,25,27,29,32–35,49,50,52,53,55 five RCTs indicated soy supplements 
effects on obese or overweight women,28,30,47,48,51 one article indicated 
soy supplements effects on postmenopausal women with abdominal 
obesity,54 two RCTs indicated soy supplements effects on post-
menopausal women with metabolic syndrome,26,31 and two RCTs indi-
cated soy supplements effects on patients with diabetes46 or 
prediabetes.36 
3.3. Risk of bias assessment 
Out of the twenty-three RCTs included in this study, one RCT was 
scored as “weak”24 seven RCTs as “fair”,25,26,35,49,50,53,55 and fifteen 
RCTs as “good”.27–34,36,46–48,51,52,54 According to blinding of partici-
pants and personals and outcome assessors, eight trials,24–2631,35,50,53,55 
and four trials24,50,53,55 displayed high risk of bias respectively. Lack of 
allocation concealment was the source of risk of bias in five 
studies.24,30,46,49,50 One study49 and four studies24,27,32,49 were consid-
ered as high risk of bias regarding incomplete outcome data and selec-
tive reporting, respectively. For further details, Table 2 presents the 
quality assessment of included RCTs. 
3.4. Findings of the meta-analysis 
Twelve studies with seventeen effect sizes evaluated soy isoflavones 
effects on serum CRP concentrations (Fig. 2). The overall effect sug-
gested a non-significant effect on serum CRP concentrations after sup-
plementation with soy isoflavones compared with comparison group 
(WMD = 0.08 mg/L, 95 % CI: -0.08, 0.24; p = 0.302). There was a 
substantial heterogeneity between studies (Cochrane’s Q test, p < 0.001; 
I2 = 87.0 %). Sensitivity analysis showed that excluding each trial from 
the overall analysis did not reveal a significant change in overall effect 
size of soy isoflavones on CRP concentration. Subgroup analysis based 
on most studied variables could not diminish the heterogeneity among 
studies (Table 3). Subgroup analyses revealed no significant change in 
circulatory levels of CRP following soy isoflavones intake compared 
with comparison group in each subgroup (except cross-over design). 
The overall effect of soy isoflavones plus soy protein on serum CRP is 
shown in Fig. 3. Eleven studies with sixteen effect sizes assessed the 
effect of soy isoflavones plus soy protein on serum CRP levels. The 
overall estimates indicated a non-significant effect on serum levels of 
CRP following soy isoflavones plus soy protein intake in comparison 
with control group (WMD= − 0.02 mg/L 95 % CI: − 0.12, 0.08; p =
0.715) with high heterogeneity (Cochrane’s Q test, p < 0.001, I2 = 84.9 
%). Sensitivity analysis showed that excluding each trial from the 
overall analysis did not reveal a significant change in overall effect size 
of soy isoflavones plus soy protein on CRP concentration. The between- 
group heterogeneity was not significant in trials using soy isoflavones 
>100 mg/d (Cochrane’s Q test, p = 0.600, I2 = 0.00 %), in trials with 
parallel design (Cochrane’s Q test, p = 0.074, I2 = 53.7 %), in trials 
performed with study duration>56 day (Cochrane’s Q test, p = 0.074, I2 
= 47.9 %) and in trials conducted in healthy people (Cochrane’s Q test, p 
= 0.330, I2 = 13.2) (Table 4). In subgroup analysis based on BMI, it was 
indicated that soy isoflavones plus soy protein could increase CRP levels 
in people with BMI ≤ 26 (p = 0.045), but a non-significant reduction 
was observed in people with BMI > 26 (p = 0.121). However, in sub-
group analysis revealed no significant change in circulatory levels of 
CRP following soy isoflavones plus soy protein intake compared with 
comparison group in other subgroups (Table 4). 
3.5. Meta-regression analysis and publication bias 
Meta-regression analysis was used to explore possible sources of 
heterogeneity and to find characteristics of participants or trials with 
effective treatment effects. The result of univariate meta-regression 
analysis didn’t show a significant linear association between soy iso-
flavones dose and effect size of soy isoflavones effect on CRP levels 
(Coefficient= − 0.0004, 95 % CI: − 0.03, 0.03; P = 0.977). Similarly, 
after adjustment for trial design, intervention duration, baseline CRP, 
participants’ health status, sample size, geographical region, age, BMI, 
quality assessment, and publication year of article, dose of soy iso-
flavones did not have any linear association with effect size of soy iso-
flavones effect on CRP levels (Coefficient = 0.009, 95 % CI: -0.11, 0.13; 
P = 0.847). We also didn’t find a significant association between other 
studied variables and effect size in univariate meta-regression analysis. 
Regarding RCTs which indicated soy isoflavones effect, funnel plot was 
Table 2 
Quality of bias assessment of the included studies according to the Cochrane guidelines.  






Blinding of participants 
and personnel 








Acharjee, 2015 25 U U H U L L Fair 
Aubertin-Leheudre, 200730 U H L U L L Good 
Azadbakht, 200726 U U H U L L Fair 
Bakhtiari, 201931 L L H L L L Good 
Christie, 201032 L L L U L H Good 
Colacurci, 200533 L U U U L L Good 
D’Anna, 200534 U U L U L L Good 
Gonźalez, 200746 L H U U L L Good 
Greany, 200835 U U H U L L Fair 
Hall, 200527 L U L U L H Good 
Jenkins, 200224 U H H H L H Weak 
Lebon, 201428 L U L L U L Good 
Liu, 201429 L L L L L L Good 
Liu, 201236 L U L L L L Good 
Llaneza, 201147 L U L L L L Good 
Llaneza, 201248 U H L L L U Good 
Mangano, 201349 L U L U H H Fair 
Nasca, 200850 U H H H L L Fair 
Riesco, 201251 U L L L L L Good 
Ryan-Borchers, 200652 L U L U L L Good 
Törmälä, 200853 U U H H L L Fair 
van Nielen, 201454 L U L L L L Good 
Yildiz, 200555 U U H H L L Fair 
L, low risk of bias; H, high risk of bias; U, unclear risk of bias. 
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not visually symmetric, but there was not any evidence of publication 
bias (Egger test p-value = 0.869 and Begg test p-value = 0.805) (Fig. 4). 
Although, univariate meta-regression analysis did not show a sig-
nificant linear association between soy isoflavones dose of combination 
of soy isoflavones plus soy protein dose and studied effect size (Coef-
ficient= − 0.008, 95 % CI: − 0.02, 0.001; P = 0.082). Also, after 
adjustment for other variables, no significant association between dose 
of soy isoflavones and studied effect size was observed (Coefficient=
− 0.005, 95 % CI: − 0.02, 0.01; P = 0.447). Although the funnel plot was 
not visually symmetric for the studies included in meta-analysis of soy 
isoflavones plus soy protein (Fig. 5), the results from the Egger and Begg 
tests did not show evidence of publication bias (Egger test p-value = p =
0.832 and Begg test p-value = 0.418). 
4. Discussion 
As far as we know, this is the first meta-analysis which reported the 
effect of soy products based on soy isoflavones and the combination of 
Fig. 2. Forest plot of the effect of soy isoflavones consumption on serum CRP concentrations.  
Table 3 
Results of subgroup analyses for studies evaluating the effect of soy isoflavones on serum CRP.   
Subgroup No. of trial Change in CRP (95% CI) P-value I2 (%) Pheterogeneity 
Total – 17 0.08 (− 0.08, 0.24) 0.302 87.0 <0.001 
Isoflavones dose (mg) 
≤80 mg/d 13 0.07 (− 0.22, 0.37) 0.627 89.6 <0.001 
>80 mg/d 4 0.00 (− 0.002, 0.002) 0.967 0.00 0.475 
Trial design 
Parallel 15 0.12 (− 0.08, 0.32) 0.243 88.0 <0.001 
Cross-over 2 − 0.13 (− 0.24, − 0.80) 0.013 0.00 0.655 
Intervention duration ≤168 day 13 0.04 (− 0.09, 0.17) 0.541 81.8 <0.001 
>168 day 4 − 0.17 (− 2.37, 2.03) 0.881 93.6 <0.001 
Baseline CRP (mg/l) 
≤3 mg/l 12 0.11 (− 0.05, 0.28) 0.174 90.4 <0.001 
>3 mg/l 5 − 0.47 (− 1.38, 0.44) 0.312 37.9 0.168 
Health status 
Healthy 5 0.08 (− 0.09, 0.26) 0.336 92.2 <0.001 
At risk/disease 12 0.0 (-0.47, 0.41) 0.887 84.7 <0.001 
Sample size ≤33 12 0.15 (− 0.12, 0.42) 0.106 89.4 <0.001 
>33 5 − 0.06 (− 0.24, 0.11) 0.671 63.9 0.026 
Geographical region 
Americas 5 0.02 (− 0.53, 0.57) 0.941 88.8 <0.001 
Europe 9 0.12 (− 0.23, 0.47) 0.516 88.2 <0.001 
Asia 3 − 0.02 (− 0.33, 0.30) 0.912 81.0 0.005 
Age 
≤57 year 9 0.24 (− 0.20, 0.67) 0.288 91.3 <0.001 
>57 year 6 − 0.14 (− 0.31, 0.02) 0.094 79.2 <0.001 
Unknown 2 0.31 (− 0.02, 0.65) 0.068 2.2 0.312 
BMI 
≤29 8 0.01 (− 0.13, 0.15) 0.923 88.2 <0.001 
>29 8 − 0.02 (− 1.16, 1.12) 0.970 85.7 <0.001 
Unknown 1 0.35 (0.18, 0.65) 0.021 – – 
Quality assessment 
Good 16 0.08 (− 0.16, 0.33) 0.520 87.5 <0.001 
Fair or weak 1 0.00 (− 0.076, 0.002) 0.981 – – 
Publication year of article 
≤2010 7 0.07 (− 0.24, 0.37) 0.678 89.0 <0.001 
>2010 10 0.09 (− 0.20, 0.38) 0.541 86.1 <0.001 
CRP: C-reactive protein, BMI: body Mass index, g/d: gram per day, mg/l: milligram per liter, mg/d: milligram per day, CI: confidence interval. 
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soy isoflavones and soy protein on serum CRP levels among post-
menopausal women. 
Our systematic review contains 23 articles which studied the effects 
of soy isoflavones and soy isoflavones plus soy protein on serum CRP 
concentration. Meta-analysis contains 19 articles with 33 datasets and 
its results indicated that soy isoflavones and soy isoflavones plus soy 
protein could not change CRP concentration among postmenopausal 
women. Our meta-analysis results confirm the result of a meta-analysis 
in year 201137 which reported the effect of overall soy products. 
Furthermore, these results revealed that new published papers with 
longer treatment duration, using higher dose of soy isoflavones or soy 
protein, and more sample size could not change the non-significant ef-
fect of soy products on serum CRP levels in previous article. The results 
of another meta-analysis regarding soy effects on postmenopausal 
Fig. 3. Forest plot of the effect of soy isoflavones plus soy protein consumption on serum CRP concentrations.  
Table 4 
Subgroup analyses for studies evaluating the effect of soy isoflavones plus soy protein on serum CRP.   
Subgroup No. of trial Change in CRP (95% CI) P-value I2 (%) Pheterogeneity 
Total – 16 − 0.02 (− 0.12, 0.08) 0.715 84.9 <0.001 
Isoflavones dose (mg) 
≤100 mg/d 9 0.23 (− 0.12, 0.57) 0.196 79.9 <0.001 
>100 mg/d 7 − 0.001 (− 0.004, 0.002) 0.622 0.00 0.600 
Protein dose (g) 
≤18 g/d 8 − 0.01 (− 0.12, 0.09) 0.812 91.1 <0.001 
>18 g/d 8 − 0.07 (− 0.32, 0.46) 0.730 65.1 0.005 
Trial design Parallel 7 0.10 (− 0.10, 0.30) 0.321 53.7 0.074 
Cross-over 9 − 0.07 (− 0.24, 0.10) 0.419 90.0 <0.001 
Intervention duration 
≤56 day 9 − 0.07 (− 0.24, 0.10) 0.419 84.9 <0.001 
>56 day 7 0.10 (− 0.10, 0.30) 0.321 47.9 0.074 
Baseline CRP (mg/l) 
≤2.5 mg/l 8 0.11 (− 0.10, 0.32) 0.313 67.2 0.003 
>2.5 mg/l 8 − 0.09 (− 0.26, 0.09) 0.330 84.0 <0.001 
Health status Healthy 5 0.004 (− 0.13, 0.12) 0.947 13.2 0.330 
At risk/disease 11 0.011(− 0.15, 0.17) 0.892 84.3 <0.001 
Sample size ≤35 8 − 0.05 (− 0.31, 0.21) 0.705 58.0 0.020 
>35 8 0.0 (− 0.12, 0.20) 0.615 86.8 <0.001 
Geographical region 
Americas 5 0.38 (− 0.1, 0.87) 0.130 68.6 0.013 
Europe 2 − 0.31 (− 1.34, 0.73) 0.562 75.4 0.044 
Asia 9 − 0.03 (− 0.18, 0.11) 0.643 83.9 <0.001 
Age 
≤58 year 8 0.11 (− 0.13, 0.36) 0.372 59.1 0.017 
>58 year 6 0.06 (− 0.43, 0.55) 0.799 66.1 0.011 
Unknown 2 − 0.10 (− 0.30, 0.10) 0.317 97.0 <0.001 
BMI 
≤26 8 0.36 (0.01, 0.72) 0.045 65.8 0.005 
>26 7 − 0.08 (− 0.18, 0.02) 0.121 91.3 <0.001 
Unknown 1 − 0.90 (− 1.79, − 0.02) 0.048 – – 
Quality assessment 
Good 7 0.06 (− 0.26, 0.38) 0.713 57.9 0.027 
Fair or weak 9 − 0.05 (− 0.16, 0.06) 0.351 90.5 <0.001 
Publication year of article 
≤2010 7 0.02 (− 0.17, 0.21) 0.833 87.7 <0.001 
>2010 9 − 0.01 (− 0.20, 0.18) 0.908 58.2 0.014 
CRP: C-reactive protein, BMI: body Mass index, g/d: gram/day, mg/l: milligram per liter, mg/d: milligram per day, CI: confidence interval. 
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women revealed beneficial effects of soy products on lipid profile.56 
There was a considerable heterogeneity between included studies 
even in most subgroup analyses. The probable reasons might be related 
to discrepancies in the ability of study papulation in metabolization and 
absorption of isoflavones, participants’ intestinal flora, dietary habit and 
genetic background of the participants. However, CRP distributions and 
the methods used in the data process were seldom reported in each trial, 
which potentially might result in heterogeneity. 
There was no significant change in serum levels of CRP in subgroup 
analysis based on dose, age, intervention duration, baseline CRP level, 
BMI, sample size, geographical region, quality assessment, publication 
year, and health status. Dose response analysis revealed no association 
of higher dose of soy isoflavones with isoflavones effect on CRP levels. 
Review articles revealed that some nutrients might have changed 
inflammatory mediators.57,58 Results of vitro,59 human60 and animal61 
studies have indicated that soy products can reduce the activity of nu-
clear factor-κB (NF-κB) as cytokine-induced signal transduction thereby 
decreases the concentration of pro-inflammatory cytokine. Furthermore, 
new evidence suggested that IL-6 by activating NF-κB is able to induce 
CRP expression.62 Therefore, in participants with health condition who 
enhance IL-6 levels, soy products by inhibition of IL-6 effect on NF-κB 
and CRP expression can reduce CRP levels, but these results were not 
confirmed in our meta-analysis. 
The absence of a significant effect in this study might have been due 
to: baseline CRP concentration, equol-producer status and duration of 
intervention. In this study, CRP levels in most included articles were in 
normal range, therefore; non-significant effect might be due to low 
levels of CRP. 
Equol is an isoflavandiol estrogen produced by the action of intes-
tinal bacteria on daidzein.63 Although equol has the superior antioxi-
dant activity in comparison with other isoflavones, most people are not 
able to produce equol. In a study by Acharjee et al., 25 it was revealed 
that taking soy products causes no significant changes in blood CRP 
levels among equol non-producing women, but equol-producers indi-
cated a significant reduction. Most articles in our meta-analysis did not 
report any information regarding equol production in participants and 
we could not perform subgroup analysis based on equol non-producers 
and equol-producers. 
According to the results obtained from subgroup analysis for soy 
isoflavones effect on CRP, there was a greater, although not significant, 
reduction among trials with a duration longer than 168 days compared 
with those with a duration shorter than 168 days. Therefore, it is 
possible that a longer period is required to produce a significant 
reduction. 
Our systematic review and meta-analysis have several limitations. 
First of all, most articles did not have any information related to equal 
production among participants; therefore, we did not assess whether 
equal production could change non-significant effect of soy products on 
CRP to significant effect among elderly subjects. Secondly, participants’ 
dietary habits were not reported in any article. Since, the dietary habits 
might change intestinal flora and the absorbed absorption amount of 
isoflavones, not considering the confounding effect of dietary habits is 
an important problem. Thirdly, most articles did not have any infor-
mation regarding medicine used by participants. Some medicine might 
have anti-inflammatory effect and change the results. Fourthly, trials 
included in this meta-analysis had small or moderate sample size. Small 
sample size does not have an adequate statistical power to detect a 
significant effect in trials and in the meta-analysis. Fifthly, no article 
measured serum levels of isoflavones; therefore, the actual absorbed 
values of isoflavones were not clarified. Sixthly, even though changes in 
fat mass are very important factor in inflammatory mediators levels, 
most RCTs did not report any information related to changes in body- 
composition. Seventhly, we did not include non-English articles. 
Our meta-analysis had a number of strengths in comparison with 
previous meta-analysis. Firstly, a large number of studies were included 
in meta-analysis; therefore, we could conduct subgroup analysis based 
on dose, trial design, health status, age, intervention duration, baseline 
CRP level, sample size, geographical region, BMI, quality assessment, 
and publication year. Secondly, we included RCTs which used only soy 
products in form of supplements or natural soy products and we 
excluded studies with other food supplements beside soy products. 
Thirdly, our meta-analysis included 19 trials from different countries; 
therefore, we limited the differences in lifestyles in this study. Fourthly, 
we reported the effect of soy isoflavones or the combination of soy 
isoflavones and soy protein separately with sufficient effect sizes. 
Fifthly, in the current study, we used a broad search terms to find all 
published studies by systematic search across multiple databases and 
also made contact with corresponding authors for clarification and 
additional data, which caused to reduce the potential misclassification 
and publication bias. Sixthly, our study was limited to RCTs and most of 
them were double-blinded which had highest quality in comparison 
with other papers. Seventhly, we did not have any limitation on publi-
cation time. 
In conclusion, according to our study results, published RCTs did not 
provide strong evidence regarding beneficial effect of soy isoflavones or 
the combination of soy isoflavones and soy protein on CRP concentra-
tion among postmenopausal women. Future studies should report soy 
effect among equol producers and non-producers and assess intestinal 
microbial composition. 
Fig. 4. Funnel plots for the studies of the effects of soy isoflavones consumption 
on serum CRP concentrations. 
Fig. 5. Funnel plots for the studies of the effects of soy isoflavones plus soy 
protein consumption on serum CRP concentrations. 
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